Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;76(1):151-156.
doi: 10.1111/his.13977.

Revising the WHO classification: female genital tract tumours

Ian A Cree  1 , Valerie A White  1 , B Iciar Indave  1 , Dilani Lokuhetty  1
Affiliations
Review

Revising the WHO classification: female genital tract tumours

Ian A Cree et al. Histopathology. 2020 Jan.

Abstract

The upcoming revision of the World Health Organisation (WHO) classification of tumours of the female genital tract is scheduled for release in the second quarter of 2020. It will feature significant changes compared to earlier editions. In this review, we outline the process of revising this important reference source for those diagnosing tumours or engaged in cancer research and describe the significant changes. The WHO classification of tumours is increasingly evidence-based, with a clear update cycle, improved quality of illustrations and content, led by an editorial board comprised mainly of pathologists, but increasingly incorporating input from other disciplines. The advent of the new website allows the use of whole-slide images and hyperlinks to evidence or external bodies that produce guidance on staging or reporting.

Keywords: cancer; classification; female; genital tract; tumour.

PubMed Disclaimer

Comment in

References

    1. Kurman RJCM, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. Bosman FTJE, Lakhani SR, Ohgaki H eds. Lyon: International Agency for Research on Cancer, 2014; 307 pp.
    1. Cree IA, Deans Z, Ligtenberg N et al. Guidance for laboratories performing molecular pathology for cancer patients. J. Clin. Pathol. 2014; 67; 923-931.
    1. Cree IA, Foss AJ, Luthert PJ. Undefined high-power fields. Lancet 1996; 347; 273-274.
    1. Sadler DW, Coghill SB. Histopathologists, malignancies, and undefined high-power fields. Lancet 1989; 1; 785-786.
    1. Travis WD, Rush W, Flieder DB et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol. 1998; 22; 934-944.

LinkOut - more resources